Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
08 Januar 2024 - 4:59PM
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, today presented a
demonstration of LOWE (Large Language Model-Orchestrated Workflow
Engine), its new software designed to perform complex drug
discovery tasks using a natural language interface. LOWE is powered
by Recursion’s proprietary biological and chemical data and can
orchestrate experiments using Recursion’s automated wet
laboratories, unleashing the power of the Recursion Operating
System in an easy-to-use tool.
“Recursion has spent the last 10 years building one of the
world’s largest biological and chemical datasets, along with
automated wet-lab and dry-lab tools that empower our scientists to
move quickly to decode biology to discover and rapidly advance
promising programs,” said Chris Gibson, Ph.D., Co-founder and CEO
of Recursion. “For the first time, we’ve taught Large Language
Models to use many of Recursion’s tools and data in the same way an
expert scientist would, but much more simply and in a more scalable
way. LOWE provides an exciting glimpse into what we believe the
future of drug discovery will look like – a first step towards the
development of autonomous ‘AI scientists’ for therapeutic
discovery.”
Chris Gibson unveiled LOWE during Recursion’s presentation at
the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
On Wednesday, January 10, Recursion and NVIDIA will co-host an
invite-only event featuring an exciting lineup of speakers and
additional software demonstrations of LOWE. Speakers at the event
will include Jensen Huang, Founder and CEO of
NVIDIA, Martin Chavez, Partner and Vice Chairman
at Sixth Street Capital and Chairman of Recursion, Aviv
Regev, Head and Executive Vice President of Research and
Early Development at Genentech, Scott Gottlieb,
Senior Fellow at the American Enterprise Institute, and Amy
Abernethy, President of Product Development and Chief
Medical Officer at Verily.
LOWE was developed at Valence Labs, Recursion’s AI research
engine, following Recursion’s acquisition of Valence Discovery in
May 2023. LOWE represents one of several initiatives Valence is
pioneering to advance the future of AI-enabled scientific
discovery, which includes the development of:
- Foundation models that accurately represent or simulate the
biological and chemical worlds of drug discovery
- Inference engines and active learners to formulate hypotheses
and learn from results
- Orchestration and reasoning systems like LOWE that can design
and execute experiments for hypothesis testing
To learn more about LOWE, visit recursion.com/lowe.
About Recursion
Recursion is a clinical stage TechBio company leading the space
by decoding biology to industrialize drug discovery. Enabling its
mission is the Recursion OS, a platform built across diverse
technologies that continuously expands one of the world’s largest
proprietary biological and chemical datasets. Recursion leverages
sophisticated machine-learning algorithms to distill from its
dataset a collection of trillions of searchable relationships
across biology and chemistry unconstrained by human bias. By
commanding massive experimental scale — up to millions of wet lab
experiments weekly — and massive computational scale — owning and
operating one of the most powerful supercomputers in the world,
Recursion is uniting technology, biology and chemistry to advance
the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montréal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on Twitter and LinkedIn.
About Valence Labs
Valence Labs, formerly Valence Discovery, is a company
industrializing scientific discovery to radically improve lives.
With roots at Mila and mentorship from Yoshua Bengio, the company
is dedicated to advancing deep learning in drug discovery,
delivering impactful research and transformative technology, and
embracing open-source and open-science knowledge sharing with the
machine learning community.
Having bested industry giants in machine learning competitions
and after gaining a deeper understanding of drug discovery
intricacies, they teamed up with Recursion to combine Valence’s
models with Recursion’s fit-for-purpose datasets to make better
predictions and choose better experiments with a lower failure
rate, at greater speed, and at a lesser cost. Combining the
intellectual freedom of academia with the resources and stability
of industry, Valence Labs takes a long-term view on technology
development: acting boldly, leaning into risks, embracing failure,
and ultimately trading incremental improvements for the
breakthrough advances they hope will redefine the field. Learn more
at www.ValenceLabs.com, or connect on Twitter and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based
upon "forward-looking statements'' within the meaning of the
Securities Litigation Reform Act of 1995, including, without
limitation, those regarding early and late stage discovery,
preclinical, and clinical programs, including timelines for data
readouts; licenses and collaborations, including option exercises
by partners and additional partnerships; prospective products and
their potential future indications and market opportunities;
Recursion OS and other technologies; business and financial plans
and performance, including cash runway; and all other statements
that are not historical facts. Forward-looking statements may or
may not include identifying words such as “plan,” “will,” “expect,”
“anticipate,” “intend,” “believe,” “potential,” “could,”
“continue,” and similar terms. These statements are subject to
known or unknown risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements, including but not limited to: challenges inherent
in pharmaceutical research and development, including the timing
and results of preclinical and clinical programs, where the risk of
failure is high and failure can occur at any stage prior to or
after regulatory approval due to lack of sufficient efficacy,
safety considerations, or other factors; our ability to leverage
and enhance our drug discovery platform; our ability to obtain
financing for development activities and other corporate purposes;
the success of our collaboration activities; our ability to obtain
regulatory approval of, and ultimately commercialize, drug
candidates; our ability to obtain, maintain, and enforce
intellectual property protections; cyberattacks or other
disruptions to our technology systems; our ability to attract,
motivate, and retain key employees and manage our growth; inflation
and other macroeconomic issues; and other risks and uncertainties
such as those described under the heading “Risk Factors” in our
filings with the U.S. Securities and Exchange Commission, including
our most recent Quarterly Report on Form 10-Q and our Annual Report
on Form 10-K. All forward-looking statements are based on
management’s current estimates, projections, and assumptions, and
Recursion undertakes no obligation to correct or update any such
statements, whether as a result of new information, future
developments, or otherwise, except to the extent required by
applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
Von Apr 2023 bis Apr 2024